Vaxart End Period Cash Flow from 2010 to 2025

VXRT Stock  USD 0.45  0.01  1.11%   
Vaxart End Period Cash Flow yearly trend continues to be comparatively stable with very little volatility. End Period Cash Flow will likely drop to about 24 M in 2025. From the period from 2010 to 2025, Vaxart End Period Cash Flow quarterly data regression had r-value of (0.06) and coefficient of variation of  78.38. View All Fundamentals
 
End Period Cash Flow  
First Reported
1989-09-30
Previous Quarter
22 M
Current Value
25.2 M
Quarterly Volatility
50.1 M
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxart financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxart's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.3 M, Interest Expense of 1.9 M or Total Revenue of 27.3 M, as well as many indicators such as Price To Sales Ratio of 44.3, Dividend Yield of 0.0 or PTB Ratio of 23.49. Vaxart financial statements analysis is a perfect complement when working with Vaxart Valuation or Volatility modules.
  
Check out the analysis of Vaxart Correlation against competitors.

Latest Vaxart's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Vaxart Inc over the last few years. It is Vaxart's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Very volatile
   End Period Cash Flow   
       Timeline  

Vaxart End Period Cash Flow Regression Statistics

Arithmetic Mean53,020,097
Geometric Mean34,323,361
Coefficient Of Variation78.38
Mean Deviation32,763,052
Median46,013,000
Standard Deviation41,559,708
Sample Variance1727.2T
Range142.7M
R-Value(0.06)
Mean Square Error1843.7T
R-Squared0
Significance0.82
Slope(533,336)
Total Sum of Squares25908.1T

Vaxart End Period Cash Flow History

202524 M
202425.2 M
202334.8 M
202246 M
2021143.7 M
2020126.9 M
201913.5 M

About Vaxart Financial Statements

Vaxart shareholders use historical fundamental indicators, such as End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Vaxart investors may analyze each financial statement separately, they are all interrelated. The changes in Vaxart's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vaxart's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow25.2 M24 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.